Look back at pharma news in the week to May 3

4 May 2019

By Barbara Obstoj-Cardwell. Editor

Among last week’s research news of note was Denmark’s diabetes care giant Novo Nordisk presentation of new data on its already blockbuster drug Victoza, clearing the path for regulatory approval in children with type 2 diabetes. Also, GlaxoSmithKline released positive new data on its triple therapy Trelegy Ellipta in asthma. On the regulatory front, Portola Pharmaceuticals gained European Union approval for its bleeding reversal agent Ondexxya. Negative news included two Complete Response Letters (CRLs) from the US Food and Drug Administration, one for Heron Therapeutics’ postoperative pain drug HTX-011 and one for Nabriva Therapeutics regarding its urinary tract infection candidate Contepo.

Novo Nordisk seeks Victoza label expansion with fresh pediatric trial results

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK